6533b86ffe1ef96bd12cd13b
RESEARCH PRODUCT
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
P. ConteP. ConteG. BisagniA. FrassoldatiA. BrandesL. CavannaF. GiottaM. AietaV. GebbiaA. MusolinoO. GarroneM. DonadioG. CavazziniA. TurlettiC. ZamagniS. DaneseA. FerroF. PiacentiniS. BalduzziR. D'amicoV. Guarnerisubject
0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinePharmaceutical AdjuvantsBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicinebusinessAdjuvantmedicine.drugEarly breast canceryear | journal | country | edition | language |
---|---|---|---|---|
2017-10-01 | Annals of Oncology |